Leflunomide

• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent… Pending
  2024-516723-14-00 Phase IV 4 countries Karolinska Institutet
• The OASE study Pending
  2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
• Discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors Pending
  2026-525316-33-00 Phase IV 1 country Sint Maartenskliniek Stichting
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 Phase III 10 countries Pfizer Inc.
• An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting
  2024-514648-10-00 Phase III 6 countries Pfizer Inc.
• Treatment with leflunomide in patients with polymyalgia rheumatica Recruiting
  2024-514210-12-00 Phase III 1 country Universitair Medisch Centrum Groningen
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting
  2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended
  2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended
  2023-510054-16-00 Phase II 7 countries Assistance Publique Hopitaux De Paris
• A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Cer… Ended
  2023-504045-31-00 Phase II 3 countries Janssen - Cilag International
• RepurpSS-II study Ended
  2024-510904-36-00 Phase II 1 country Universitair Medisch Centrum Utrecht
• RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol… Ended
  2023-510189-28-00 Phase IV 1 country UZ Leuven

Showing 1–14 of 14 trials